Treatment Details - 7.0 months - Surviving Mesothelioma

Treatment Details – 7.0 months

Survival: 7.0 months
   
Toxicity Grade: 3
   
Treatments: Chemotherapy
   
Drugs:
Country: Netherlands
   
City/State/Province: Amsterdam
   
Hospital: The Netherlands Cancer Institute
   
Journal: Link
   
Date: 2/2003

Description:
Patients: This Phase II study involved 24 patients with malignant pleural mesothelioma; 19 men and 5 women. The median age was 63 years.

Treatment: The treatment consisted of the drug raltitrexed (tomudex). This agent inhibits the enzyme thymidylate synthase which is involved in the synthesis of DNA.

Toxicity: Grade 3-4 toxicities included anorexia, shortness of breath/dyspnea, hematologic, febrile neutropenia, nausea/vomiting, neurological toxicity, chest pain, pleuritic pain, and cough.

Results: The overall median survival was 7 months.

Support: AstraZeneca provided the drug (Tomudex) free of charge.

Correspondence: P. Baas, MD

Get your free copy of
Surviving Mesothelioma Today!